| Title: |
Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia |
| Authors: |
Suh, CH; Lee, Y; Yoo, SB; Quasny, H; Navarro Rojas, AA; Hammer, A; Song, YW; Kang, YM; Cho, CS; Park, W; Kwok, SK; Lee, SG; Chung, WT; Bae, SC |
| Contributors: |
104467; Suh, CH |
| Publication Year: |
2024 |
| Subject Terms: |
Antibodies; Monoclonal; Humanized; Asia; Eastern; Double-Blind Method; Humans; Immunosuppressive Agents; Lupus Erythematosus; Systemic; Republic of Korea; Severity of Illness Index; Treatment Outcome; belimumab; efficacy; safety; South Korea; systemic lupus erythematosus |
| Description: |
Aim: This post hoc analysis evaluated the efficacy and safety of intravenous belimumab 10 mg/kg in the South Korean subgroup of patients with systemic lupus erythematosus (SLE) enrolled in the North East Asia (NEA) study (GSK Study BEL113750; NCT01345253). Methods: NEA was a double-blind, placebo-controlled, randomized Phase 3 trial. Patients with active, autoantibody-positive SLE were randomized 2:1 to belimumab or placebo plus standard therapy administered on Days 0, 14, and 28, and then every 28 days up to Week 48. The primary efficacy endpoint in this analysis was SLE Responder Index 4 (SRI-4) response rate at Week 52, defined as the proportion of patients achieving a ≥4-point reduction in Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score, no worsening ( |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
J017561841; http://repository.ajou.ac.kr/handle/201003/32445 |
| DOI: |
10.1111/1756-185X.14997 |
| Availability: |
http://repository.ajou.ac.kr/handle/201003/32445; https://doi.org/10.1111/1756-185X.14997 |
| Accession Number: |
edsbas.4B6A1698 |
| Database: |
BASE |